Kidney cancer: now available in a new flavor
- PMID: 19061830
- DOI: 10.1016/j.ccr.2008.11.005
Kidney cancer: now available in a new flavor
Abstract
The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they produce both HIF2alpha and HIF1alpha or HIF2alpha alone.
Comment on
-
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.Cancer Cell. 2008 Dec 9;14(6):435-46. doi: 10.1016/j.ccr.2008.10.016. Cancer Cell. 2008. PMID: 19061835 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
